Vertex Pharmaceuticals Incorporated (VRTX) has a consensus analyst rating of Buy, based on 55 analysts covering the stock. Of those, 47 recommend buying, 8 recommend holding, and 0 recommend selling.
The analyst consensus price target for VRTX is $549.73, representing a +23.7% upside from the current price of $444.28. Price targets range from a low of $441.00 to a high of $607.00.
